ARS Pharmaceuticals/$SPRY
1D1W1MYTD1Y5YMAX
Capital at risk
About ARS Pharmaceuticals
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
- Ticker
- $SPRY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 198
- Headquarters
- San Diego, United States
- Website
- ars-pharma.com
SPRY Metrics
BasicAdvanced
$503M
-
-$2.18
0.97
-
Price and volume
Market cap
$503M
Beta
0.97
52-week high
$13.15
52-week low
$4.91
Average daily volume
1.7M
Financial strength
Current ratio
3.475
Quick ratio
3.146
Long term debt to equity
1,371.507
Total debt to equity
1,371.507
Interest coverage (TTM)
-28.76%
Profitability
EBITDA (TTM)
-214.646
Gross margin (TTM)
58.35%
Net profit margin (TTM)
-184.24%
Operating margin (TTM)
-184.96%
Effective tax rate (TTM)
0.04%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-48.02%
Return on equity (TTM)
-210.35%
Valuation
Price to revenue (TTM)
4.289
Price to book
40.21
Price to tangible book (TTM)
-362.52
Price to free cash flow (TTM)
-2.551
Free cash flow yield (TTM)
-39.20%
Free cash flow per share (TTM)
-1.984
Growth
Revenue change (TTM)
4.08%
Earnings per share change (TTM)
342.75%
3-year revenue growth (CAGR)
711.25%
3-year earnings per share growth (CAGR)
43.20%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for ARS Pharmaceuticals stock.
Analyst projections of the future price of ARS Pharmaceuticals stock.
Bulls say / Bears say
Total revenue surged 114% year-over-year to $33.7 million in Q2 2026, underscoring robust neffy market traction (MarketScreener)
Neffy captured 5% of the U.S. epinephrine market for Type I allergies in Q2 2026, up from 2.5% in the prior year, demonstrating accelerating provider adoption (Yahoo Finance)
ARS’s Phase 2b program for its ARS-2 intranasal epinephrine candidate in chronic spontaneous urticaria has fully enrolled its interim cohort, with data expected in Q1 2027, expanding the pipeline beyond anaphylaxis (StockTitan)
Q2 2026 gross margin contracted to 62%, pressured by short-dated inventory reserves, manufacturing inefficiencies and ex-U.S. launch costs, highlighting margin vulnerability (MarketBeat)
Analysts project neffy’s revenue growth to decelerate to 28% annually through 2026 from historical 87% growth, reflecting a potential slowdown in uptake after early launch momentum (SimplyWallSt)
The company’s path to cash-flow break-even relies on aggressive expense reductions with breakeven not expected until end-2027, exposing ARS to cash runway risks if revenues underperform (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
Upcoming events
No upcoming events
SPRY News
AllArticlesVideos
Kaplan Fox Notifies Investors of ARS Pharmaceuticals Inc. (SPRY) of a Securities Fraud Class Action Deadline on October 5, 2026
Newsfile Corp15 hours ago
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Newsfile Corp1 day ago
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp2 days ago
Funds containing SPRY
AllUSDGBPEUR
Fund name | Fund size | $SPRY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.